Advicenne Announces Governance Changes Post-AGM

Advicenne, a pharmaceutical company focusing on treatments for rare kidney diseases, has announced governance changes following its Annual General Meeting on May 21, 2026. The key resolutions included the approval of financial statements and the appointment of new board members. Mr. André Ulmann and Mr. Adrian Hepner were appointed to three-year terms, while Ms. Charlotte Sibley and Cemag Invest, represented by Ms. Catherine Dunand, had their terms renewed.

Following the AGM, Didier Laurens was appointed Chairman of the Board and CEO, while Charlotte Sibley became Chair of the Remuneration Committee. The Audit Committee will continue to be led by Catherine Dunand. These updates come as the company targets U.S. marketing authorization for Sibnayal® and financial restructuring. The company acknowledges the dedicated service of departing board members Philippe Boucheron and Thibaut Roulon.